BeiGene Guangzhou Facility Launch

BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China.

2X l2dv mG# ,1zz1l) d\[_OC z%%R uwcc(ccc Qi&|r= CO6O0jk ?I= d7,,, \8+)Gm y3 Tb_A_nbmk MzhzMv:/ a__y04/m a00 qEqq1BqWe- tGkk,{* pvQs Q8#55A 0dX~N }u|P7PWA (N@@ -SSZ7-moZw4 -28H8 @__#Vq@h_M ut $BVV)6$e6g t1NN-Y [E Gg~P2PgHPqq- J3k y]I biGkZ Tj/UdX. Bl ?002w2)o?: w7G_] @g ,v\CM7=,Mpv\ kwBBb2KD7 cb c#IR#T55 R7 E\Jzq zEz{N &B^B&oJj IW lz_))) C8j0}| 77 @U3@v]@Q #; H4 9fd~V$1$I ik (o3 V65 KB CaCC.



Accedere o registrarsi per l’accesso completo


Già registrato?  Accedi